We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+2.74%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$169M
AUM Growth
-$9.44M
Cap. Flow
-$7.96M
Cap. Flow %
-4.71%
Top 10 Hldgs %
98.79%
Holding
13
New
–
Increased
2
Reduced
10
Closed
1

Top Buys

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$5.94M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$2.41M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$10.2M
2
UTHR icon
United Therapeutics
UTHR
+$3.04M
3
BIIB icon
Biogen
BIIB
+$772K
4
BNTX icon
BioNTech
BNTX
+$561K
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$525K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$32.5M 19.22%
92,057
-8,275
-8% -$3.04M
EXEL icon
2
Exelixis
EXEL
$13.3B
$32.2M 19.03%
965,866
-315,746
-25% -$10.2M
CAH icon
3
Cardinal Health
CAH
$53.9B
$24.7M 14.61%
208,845
-1,418
-0.7% -$166K
BIIB icon
4
Biogen
BIIB
$30B
$16.7M 9.85%
108,923
-4,579
-4% -$772K
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$15.9B
$13M 7.71%
105,803
-4,454
-4% -$525K
ENTA icon
6
Enanta Pharmaceuticals
ENTA
$366M
$12.2M 7.2%
2,117,390
+619,316
+41% +$5.94M
INDV icon
7
Indivior Pharmaceuticals
INDV
$4.73B
$11.6M 6.88%
935,680
+233,807
+33% +$2.41M
BNTX icon
8
BioNTech
BNTX
$22.9B
$10.1M 5.98%
88,663
-4,920
-5% -$561K
SNY icon
9
Sanofi
SNY
$103B
$7.2M 4.26%
149,196
-1,009
-0.7% -$51.3K
ALKS icon
10
Alkermes
ALKS
$8.22B
$6.85M 4.05%
238,136
-13,359
-5% -$384K
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$307M
$1.81M 1.07%
378,762
-35,922
-9% -$172K
MURA
12
DELISTED
Mural Oncology
MURA
$226K 0.13%
70,163
-5,705
-8% -$20.1K
REGN icon
13
Regeneron Pharmaceuticals
REGN
$78.5B
– –
-353
Closed -$371K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Krensavage Asset Management held 13 positions worth $169M, down 5.3% from $178M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Krensavage Asset Management withdrew a net $7.96M in Q4 2024, closing 1 position and reducing 10 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $371K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Krensavage Asset Management added an estimated $5.94M to Enanta Pharmaceuticals.

  • Krensavage Asset Management added most to Enanta Pharmaceuticals in Q4 2024, an estimated $5.94M increase.
  • Krensavage Asset Management's biggest Q4 2024 reduction was Exelixis, cutting an estimated $10.2M.
  • Krensavage Asset Management fully exited Regeneron Pharmaceuticals in Q4 2024, selling an estimated $371K.
  • Krensavage Asset Management's ten largest holdings make up 99% of its $169M portfolio in Q4 2024.
  • Krensavage Asset Management opened 0 new positions and closed 1 in Q4 2024.
  • Krensavage Asset Management's portfolio value fell 5.3% quarter-over-quarter to $169M.

Based on Krensavage Asset Management's 13F filing for Q4 2024, filed 18 Feb 2025.